Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers

FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers

Oct 29, 2019
|
Turna Ray
Premium

NEW YORK – The latest approval of niraparib (GlaxoSmithKline's Zejula) for heavily pretreated ovarian cancer patients with homologous recombination deficiency (HRD) not only increases the number of patients eligible for the drug, but also adds another biomarker that oncologists can use to help them decide whether to prescribe this PARP inhibitor or another drug. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Robots for the Lab

Researchers have developed a robotic lab assistant, the Verge reports.

Ruling Awaited

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

To Find Where It Came From

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

Science Presents Atlas of Aberrant Cells in Lung Condition, More

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

Sponsored by
Agilent

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
22
Featured Webinar

Advances in Genetic Testing for IVF Research: PGT-A, PGT-M, and Carrier Screening

Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  2. Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

  3. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

  4. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  5. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.